Shire Plc (LON:SHP) Rating
Goldman Sachs have a GBX 6300.00 TP on the stock. The TP would suggest a potential upside of 22.57% from Shire Plc (LON:SHP)’s current stock price. This rating was revealed in an analyst report on Thursday morning.
Out of 23 analysts covering Shire PLC (LON:SHP), 20 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 87% are positive. GBX 6600 is the highest target while GBX 234 is the lowest. The GBX 5254.70 average target is 2.15% above today’s (GBX 5144) stock price. Shire PLC has been the topic of 167 analyst reports since October 5, 2015 according to StockzIntelligence Inc. Goldman Sachs maintained the stock on September 29 with “Conviction Buy” rating. Liberum Capital maintained it with “Buy” rating and GBX 5500 target price in a September 19 report. HSBC maintained the shares of SHP in a report on September 28 with “Hold” rating. UBS maintained the firm’s rating on September 19. UBS has “Buy” rating and GBX 5600 price target. Lastly, Berenberg maintained the stock with “Buy” rating in a September 27 report.
About 234,325 shares traded hands. Shire PLC (LON:SHP) has risen 34.85% since February 29, 2016 and is uptrending. It has outperformed by 23.59% the S&P500.
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of 46.41 billion GBP. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 31.9 P/E ratio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.